Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings
| العنوان: | Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings |
|---|---|
| المؤلفون: | Maria Cristina Marazzi, Giuseppe Liotta, A Doro Altan, Massimo Magnano San Lio, P Germano, Leonardo Palombi, Karin Nielsen-Saines, Giovanni Guidotti, Susanna Ceffa |
| بيانات النشر: | Mary Ann Liebert Incorporated, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | blood toxicity, CD4-Positive T-Lymphocytes, Male, Pediatrics, Malawi, nevirapine, proportional hazards model, Settore MED/42 - Igiene Generale e Applicata, Human immunodeficiency virus 1, HIV Infections, Tanzania, Cohort Studies, Risk Factors, Antiretroviral Therapy, Highly Active, health center, Sida, Mozambique, combination chemotherapy, biology, Mortality rate, adult, article, virus diseases, Anemia, highly active antiretroviral therapy, cohort analysis, liver toxicity, zidovudine, Infectious Diseases, female, Treatment Outcome, priority journal, risk factor, Cohort, disease severity, Viral disease, lamivudine, Viral load, medicine.medical_specialty, stavudine, Anti-HIV Agents, Immunology, Antiretroviral Therapy, nelfinavir, Acquired immunodeficiency syndrome (AIDS), Virology, medicine, follow up, Humans, Medical history, controlled study, Highly Active, human, Developing Countries, virus detection, Proportional Hazards Models, Retrospective Studies, treatment duration, hemoglobin blood level, business.industry, Malnutrition, CD4 lymphocyte count, treatment response, Retrospective cohort study, hemoglobin, virus load, biology.organism_classification, medicine.disease, Human immunodeficiency virus 1 infection, major clinical study, mortality, cotrimoxazole, body mass, Surgery, world health organization, HIV-1, anamnesis, business, male, Adult, CD4 Lymphocyte Count, Female |
| الوصف: | The response to treatment and risk factors for early mortality following initiation of combination antiretrovirals(ARVs) in a cohort of African patients are described in a retrospective cohort design. Medical history, laboratory parameters, and mortality data were reviewed for patients initiating ARVs in 12 clinical centers in Mozambique, Tanzania, and Malawi. Among 3456 HIV-1-infected patients who received ARVs for more than 6 months, at baseline 72% had WHO clinical stages 3/4, 7% had a viral load 400 copies/ml, and 38% had a CD4 cell count200/microl. One year later, 78% had undetectable virus loads and 79% had CD4 cell counts200 cells/mm3. In the first year of HAART 260 deaths occurred (97 per 1000 person/years) with mortality peaking in the first 3 months. The highest mortality was observed in patients with low BMI, low hemoglobin levels, and CD4 values200 cells/microl at baseline. Mortality rates following initiation of HAART are higher in patients in resource-limited areas, particularly in the first 90 days following treatment initiation.HAART initiated at higher CD4 cell count levels, especially among malnourished and/or anemic patients, will carry significant public health impact. |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9f5e45e00e8154b30bd06abed774faTest http://hdl.handle.net/2108/38575Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....8d9f5e45e00e8154b30bd06abed774fa |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....8d9f5e45e00e8154b30bd06abed774fa 766 3 unknown 765.664306640625 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8d9f5e45e00e8154b30bd06abed774fa&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Maria+Cristina+Marazzi%22">Maria Cristina Marazzi</searchLink><br /><searchLink fieldCode="AR" term="%22Giuseppe+Liotta%22">Giuseppe Liotta</searchLink><br /><searchLink fieldCode="AR" term="%22A+Doro+Altan%22">A Doro Altan</searchLink><br /><searchLink fieldCode="AR" term="%22Massimo+Magnano+San+Lio%22">Massimo Magnano San Lio</searchLink><br /><searchLink fieldCode="AR" term="%22P+Germano%22">P Germano</searchLink><br /><searchLink fieldCode="AR" term="%22Leonardo+Palombi%22">Leonardo Palombi</searchLink><br /><searchLink fieldCode="AR" term="%22Karin+Nielsen-Saines%22">Karin Nielsen-Saines</searchLink><br /><searchLink fieldCode="AR" term="%22Giovanni+Guidotti%22">Giovanni Guidotti</searchLink><br /><searchLink fieldCode="AR" term="%22Susanna+Ceffa%22">Susanna Ceffa</searchLink> ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Mary Ann Liebert Incorporated, 2008. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2008 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22blood+toxicity%22">blood toxicity</searchLink><br /><searchLink fieldCode="DE" term="%22CD4-Positive+T-Lymphocytes%22">CD4-Positive T-Lymphocytes</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Pediatrics%22">Pediatrics</searchLink><br /><searchLink fieldCode="DE" term="%22Malawi%22">Malawi</searchLink><br /><searchLink fieldCode="DE" term="%22nevirapine%22">nevirapine</searchLink><br /><searchLink fieldCode="DE" term="%22proportional+hazards+model%22">proportional hazards model</searchLink><br /><searchLink fieldCode="DE" term="%22Settore+MED%2F42+-+Igiene+Generale+e+Applicata%22">Settore MED/42 - Igiene Generale e Applicata</searchLink><br /><searchLink fieldCode="DE" term="%22Human+immunodeficiency+virus+1%22">Human immunodeficiency virus 1</searchLink><br /><searchLink fieldCode="DE" term="%22HIV+Infections%22">HIV Infections</searchLink><br /><searchLink fieldCode="DE" term="%22Tanzania%22">Tanzania</searchLink><br /><searchLink fieldCode="DE" term="%22Cohort+Studies%22">Cohort Studies</searchLink><br /><searchLink fieldCode="DE" term="%22Risk+Factors%22">Risk Factors</searchLink><br /><searchLink fieldCode="DE" term="%22Antiretroviral+Therapy%2C+Highly+Active%22">Antiretroviral Therapy, Highly Active</searchLink><br /><searchLink fieldCode="DE" term="%22health+center%22">health center</searchLink><br /><searchLink fieldCode="DE" term="%22Sida%22">Sida</searchLink><br /><searchLink fieldCode="DE" term="%22Mozambique%22">Mozambique</searchLink><br /><searchLink fieldCode="DE" term="%22combination+chemotherapy%22">combination chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22biology%22">biology</searchLink><br /><searchLink fieldCode="DE" term="%22Mortality+rate%22">Mortality rate</searchLink><br /><searchLink fieldCode="DE" term="%22adult%22">adult</searchLink><br /><searchLink fieldCode="DE" term="%22article%22">article</searchLink><br /><searchLink fieldCode="DE" term="%22virus+diseases%22">virus diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Anemia%22">Anemia</searchLink><br /><searchLink fieldCode="DE" term="%22highly+active+antiretroviral+therapy%22">highly active antiretroviral therapy</searchLink><br /><searchLink fieldCode="DE" term="%22cohort+analysis%22">cohort analysis</searchLink><br /><searchLink fieldCode="DE" term="%22liver+toxicity%22">liver toxicity</searchLink><br /><searchLink fieldCode="DE" term="%22zidovudine%22">zidovudine</searchLink><br /><searchLink fieldCode="DE" term="%22Infectious+Diseases%22">Infectious Diseases</searchLink><br /><searchLink fieldCode="DE" term="%22female%22">female</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+Outcome%22">Treatment Outcome</searchLink><br /><searchLink fieldCode="DE" term="%22priority+journal%22">priority journal</searchLink><br /><searchLink fieldCode="DE" term="%22risk+factor%22">risk factor</searchLink><br /><searchLink fieldCode="DE" term="%22Cohort%22">Cohort</searchLink><br /><searchLink fieldCode="DE" term="%22disease+severity%22">disease severity</searchLink><br /><searchLink fieldCode="DE" term="%22Viral+disease%22">Viral disease</searchLink><br /><searchLink fieldCode="DE" term="%22lamivudine%22">lamivudine</searchLink><br /><searchLink fieldCode="DE" term="%22Viral+load%22">Viral load</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22stavudine%22">stavudine</searchLink><br /><searchLink fieldCode="DE" term="%22Anti-HIV+Agents%22">Anti-HIV Agents</searchLink><br /><searchLink fieldCode="DE" term="%22Immunology%22">Immunology</searchLink><br /><searchLink fieldCode="DE" term="%22Antiretroviral+Therapy%22">Antiretroviral Therapy</searchLink><br /><searchLink fieldCode="DE" term="%22nelfinavir%22">nelfinavir</searchLink><br /><searchLink fieldCode="DE" term="%22Acquired+immunodeficiency+syndrome+%28AIDS%29%22">Acquired immunodeficiency syndrome (AIDS)</searchLink><br /><searchLink fieldCode="DE" term="%22Virology%22">Virology</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22follow+up%22">follow up</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+history%22">Medical history</searchLink><br /><searchLink fieldCode="DE" term="%22controlled+study%22">controlled study</searchLink><br /><searchLink fieldCode="DE" term="%22Highly+Active%22">Highly Active</searchLink><br /><searchLink fieldCode="DE" term="%22human%22">human</searchLink><br /><searchLink fieldCode="DE" term="%22Developing+Countries%22">Developing Countries</searchLink><br /><searchLink fieldCode="DE" term="%22virus+detection%22">virus detection</searchLink><br /><searchLink fieldCode="DE" term="%22Proportional+Hazards+Models%22">Proportional Hazards Models</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+Studies%22">Retrospective Studies</searchLink><br /><searchLink fieldCode="DE" term="%22treatment+duration%22">treatment duration</searchLink><br /><searchLink fieldCode="DE" term="%22hemoglobin+blood+level%22">hemoglobin blood level</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Malnutrition%22">Malnutrition</searchLink><br /><searchLink fieldCode="DE" term="%22CD4+lymphocyte+count%22">CD4 lymphocyte count</searchLink><br /><searchLink fieldCode="DE" term="%22treatment+response%22">treatment response</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+cohort+study%22">Retrospective cohort study</searchLink><br /><searchLink fieldCode="DE" term="%22hemoglobin%22">hemoglobin</searchLink><br /><searchLink fieldCode="DE" term="%22virus+load%22">virus load</searchLink><br /><searchLink fieldCode="DE" term="%22biology%2Eorganism%5Fclassification%22">biology.organism_classification</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Human+immunodeficiency+virus+1+infection%22">Human immunodeficiency virus 1 infection</searchLink><br /><searchLink fieldCode="DE" term="%22major+clinical+study%22">major clinical study</searchLink><br /><searchLink fieldCode="DE" term="%22mortality%22">mortality</searchLink><br /><searchLink fieldCode="DE" term="%22cotrimoxazole%22">cotrimoxazole</searchLink><br /><searchLink fieldCode="DE" term="%22body+mass%22">body mass</searchLink><br /><searchLink fieldCode="DE" term="%22Surgery%22">Surgery</searchLink><br /><searchLink fieldCode="DE" term="%22world+health+organization%22">world health organization</searchLink><br /><searchLink fieldCode="DE" term="%22HIV-1%22">HIV-1</searchLink><br /><searchLink fieldCode="DE" term="%22anamnesis%22">anamnesis</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22male%22">male</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22CD4+Lymphocyte+Count%22">CD4 Lymphocyte Count</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The response to treatment and risk factors for early mortality following initiation of combination antiretrovirals(ARVs) in a cohort of African patients are described in a retrospective cohort design. Medical history, laboratory parameters, and mortality data were reviewed for patients initiating ARVs in 12 clinical centers in Mozambique, Tanzania, and Malawi. Among 3456 HIV-1-infected patients who received ARVs for more than 6 months, at baseline 72% had WHO clinical stages 3/4, 7% had a viral load 400 copies/ml, and 38% had a CD4 cell count200/microl. One year later, 78% had undetectable virus loads and 79% had CD4 cell counts200 cells/mm3. In the first year of HAART 260 deaths occurred (97 per 1000 person/years) with mortality peaking in the first 3 months. The highest mortality was observed in patients with low BMI, low hemoglobin levels, and CD4 values200 cells/microl at baseline. Mortality rates following initiation of HAART are higher in patients in resource-limited areas, particularly in the first 90 days following treatment initiation.HAART initiated at higher CD4 cell count levels, especially among malnourished and/or anemic patients, will carry significant public health impact. ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9f5e45e00e8154b30bd06abed774fa" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9f5e45e00e8154b30bd06abed774fa</link><br /><link linkTarget="URL" linkTerm="http://hdl.handle.net/2108/38575" linkWindow="_blank">http://hdl.handle.net/2108/38575</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CLOSED ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....8d9f5e45e00e8154b30bd06abed774fa ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => blood toxicity
[Type] => general
)
[1] => Array
(
[SubjectFull] => CD4-Positive T-Lymphocytes
[Type] => general
)
[2] => Array
(
[SubjectFull] => Male
[Type] => general
)
[3] => Array
(
[SubjectFull] => Pediatrics
[Type] => general
)
[4] => Array
(
[SubjectFull] => Malawi
[Type] => general
)
[5] => Array
(
[SubjectFull] => nevirapine
[Type] => general
)
[6] => Array
(
[SubjectFull] => proportional hazards model
[Type] => general
)
[7] => Array
(
[SubjectFull] => Settore MED/42 - Igiene Generale e Applicata
[Type] => general
)
[8] => Array
(
[SubjectFull] => Human immunodeficiency virus 1
[Type] => general
)
[9] => Array
(
[SubjectFull] => HIV Infections
[Type] => general
)
[10] => Array
(
[SubjectFull] => Tanzania
[Type] => general
)
[11] => Array
(
[SubjectFull] => Cohort Studies
[Type] => general
)
[12] => Array
(
[SubjectFull] => Risk Factors
[Type] => general
)
[13] => Array
(
[SubjectFull] => Antiretroviral Therapy, Highly Active
[Type] => general
)
[14] => Array
(
[SubjectFull] => health center
[Type] => general
)
[15] => Array
(
[SubjectFull] => Sida
[Type] => general
)
[16] => Array
(
[SubjectFull] => Mozambique
[Type] => general
)
[17] => Array
(
[SubjectFull] => combination chemotherapy
[Type] => general
)
[18] => Array
(
[SubjectFull] => biology
[Type] => general
)
[19] => Array
(
[SubjectFull] => Mortality rate
[Type] => general
)
[20] => Array
(
[SubjectFull] => adult
[Type] => general
)
[21] => Array
(
[SubjectFull] => article
[Type] => general
)
[22] => Array
(
[SubjectFull] => virus diseases
[Type] => general
)
[23] => Array
(
[SubjectFull] => Anemia
[Type] => general
)
[24] => Array
(
[SubjectFull] => highly active antiretroviral therapy
[Type] => general
)
[25] => Array
(
[SubjectFull] => cohort analysis
[Type] => general
)
[26] => Array
(
[SubjectFull] => liver toxicity
[Type] => general
)
[27] => Array
(
[SubjectFull] => zidovudine
[Type] => general
)
[28] => Array
(
[SubjectFull] => Infectious Diseases
[Type] => general
)
[29] => Array
(
[SubjectFull] => female
[Type] => general
)
[30] => Array
(
[SubjectFull] => Treatment Outcome
[Type] => general
)
[31] => Array
(
[SubjectFull] => priority journal
[Type] => general
)
[32] => Array
(
[SubjectFull] => risk factor
[Type] => general
)
[33] => Array
(
[SubjectFull] => Cohort
[Type] => general
)
[34] => Array
(
[SubjectFull] => disease severity
[Type] => general
)
[35] => Array
(
[SubjectFull] => Viral disease
[Type] => general
)
[36] => Array
(
[SubjectFull] => lamivudine
[Type] => general
)
[37] => Array
(
[SubjectFull] => Viral load
[Type] => general
)
[38] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[39] => Array
(
[SubjectFull] => stavudine
[Type] => general
)
[40] => Array
(
[SubjectFull] => Anti-HIV Agents
[Type] => general
)
[41] => Array
(
[SubjectFull] => Immunology
[Type] => general
)
[42] => Array
(
[SubjectFull] => Antiretroviral Therapy
[Type] => general
)
[43] => Array
(
[SubjectFull] => nelfinavir
[Type] => general
)
[44] => Array
(
[SubjectFull] => Acquired immunodeficiency syndrome (AIDS)
[Type] => general
)
[45] => Array
(
[SubjectFull] => Virology
[Type] => general
)
[46] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[47] => Array
(
[SubjectFull] => follow up
[Type] => general
)
[48] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[49] => Array
(
[SubjectFull] => Medical history
[Type] => general
)
[50] => Array
(
[SubjectFull] => controlled study
[Type] => general
)
[51] => Array
(
[SubjectFull] => Highly Active
[Type] => general
)
[52] => Array
(
[SubjectFull] => human
[Type] => general
)
[53] => Array
(
[SubjectFull] => Developing Countries
[Type] => general
)
[54] => Array
(
[SubjectFull] => virus detection
[Type] => general
)
[55] => Array
(
[SubjectFull] => Proportional Hazards Models
[Type] => general
)
[56] => Array
(
[SubjectFull] => Retrospective Studies
[Type] => general
)
[57] => Array
(
[SubjectFull] => treatment duration
[Type] => general
)
[58] => Array
(
[SubjectFull] => hemoglobin blood level
[Type] => general
)
[59] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[60] => Array
(
[SubjectFull] => Malnutrition
[Type] => general
)
[61] => Array
(
[SubjectFull] => CD4 lymphocyte count
[Type] => general
)
[62] => Array
(
[SubjectFull] => treatment response
[Type] => general
)
[63] => Array
(
[SubjectFull] => Retrospective cohort study
[Type] => general
)
[64] => Array
(
[SubjectFull] => hemoglobin
[Type] => general
)
[65] => Array
(
[SubjectFull] => virus load
[Type] => general
)
[66] => Array
(
[SubjectFull] => biology.organism_classification
[Type] => general
)
[67] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[68] => Array
(
[SubjectFull] => Human immunodeficiency virus 1 infection
[Type] => general
)
[69] => Array
(
[SubjectFull] => major clinical study
[Type] => general
)
[70] => Array
(
[SubjectFull] => mortality
[Type] => general
)
[71] => Array
(
[SubjectFull] => cotrimoxazole
[Type] => general
)
[72] => Array
(
[SubjectFull] => body mass
[Type] => general
)
[73] => Array
(
[SubjectFull] => Surgery
[Type] => general
)
[74] => Array
(
[SubjectFull] => world health organization
[Type] => general
)
[75] => Array
(
[SubjectFull] => HIV-1
[Type] => general
)
[76] => Array
(
[SubjectFull] => anamnesis
[Type] => general
)
[77] => Array
(
[SubjectFull] => business
[Type] => general
)
[78] => Array
(
[SubjectFull] => male
[Type] => general
)
[79] => Array
(
[SubjectFull] => Adult
[Type] => general
)
[80] => Array
(
[SubjectFull] => CD4 Lymphocyte Count
[Type] => general
)
[81] => Array
(
[SubjectFull] => Female
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Maria Cristina Marazzi
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Giuseppe Liotta
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => A Doro Altan
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Massimo Magnano San Lio
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => P Germano
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Leonardo Palombi
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Karin Nielsen-Saines
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Giovanni Guidotti
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Susanna Ceffa
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2008
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
)
)
)
)
)
|
| IllustrationInfo |